The overview of modern approaches in treatment of triple negative breast cancer
Open Access
- 12 March 2020
- journal article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 7 (1), 55-65
- https://doi.org/10.17709/2409-2231-2020-7-1-6
Abstract
By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance. The review presents the results of modern regimens of drug therapy of triple negative breast cancer according to the publications of domestic and foreign oncologists. On the basis of various clinical studies, the effectiveness of the use of anthracyclines, taxanes in the dose-dense regime, platinum preparations and other chemotherapy drugs for the treatment of triple-negative cancer has been shown. The presented treatment regimens allow to achieve a complete morphological response in 85% of patients, to increase the rates of relapse-free and overall survival, comparable with other subtypes of breast cancer. The review highlights the possibilities of modern targeted drugs-PARP inhibitors, chk1 inhibitors UCN‑01, immunotherapy possibilities for the treatment of this aggressive subtype of breast cancer.Keywords
This publication has 27 references indexed in Scilit:
- TREATMENT OF TRIPLE-NEGATIVE BREAST CANCERTumors of female reproductive system, 2017
- COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCERTumors of female reproductive system, 2017
- The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological DispensaryTumors of female reproductive system, 2016
- EVALUATION OF EFFICACY AND TOXICITY OF NEOADJUVANT CHEMOTHERAPY WITH DOSE-DENSE DOXORUBICIN, CISPLATIN, AND PACLITAXEL IN PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCERMalignant tumours, 2016
- Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesisJCI Insight, 2012
- Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotypeEuropean Journal of Cancer, 2011
- Triple-Negative Breast CancerThe New England Journal of Medicine, 2010
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer, 2009
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to ChemotherapyJNCI Journal of the National Cancer Institute, 2008
- In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot studyAnnals of Oncology, 2005